J. H. Schellens

发表

Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer.

J. Schellens, J. V. van Sandick, H. Boot, 2015, Critical reviews in oncology/hematology.

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

J. Schellens, J. Beijnen, A. Huitema, 2013, Gynecologic oncology.

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

J. Wanders, P. Fumoleau, J. Schellens, 2003, British Journal of Cancer.

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin

J. Schellens, J. Hasselt, J. Beijnen, 2015, CPT: pharmacometrics & systems pharmacology.

Inherent formulation issues of kinase inhibitors.

J. Schellens, B. Nuijen, M. Herbrink, 2016, Journal of controlled release : official journal of the Controlled Release Society.

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

R. Plummer, M. Ranson, J. Schellens, 2016, Investigational New Drugs.

Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique.

J. Schellens, J. Beijnen, B. Nuijen, 2016, Cancer treatment reviews.

DNA-based drug interactions of cisplatin.

J. Schellens, J. Beijnen, R. V. van Waardenburg, 2002, Cancer treatment reviews.

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

L. Chirieac, R. Plummer, M. Ranson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor-Mediated CYP3A4 Induction

I. Meijerman, S. Harmsen, J. H. Beijnen, 2008, Drug Metabolism and Disposition.

Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor Mediated Cyp3a4 Induction Dmd #17335 2 Ls180 as a Model to Study Cyp3a4 Induction

I. Meijerman, S. Harmsen, J. H. Beijnen, 2022 .

Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin

J. Schellens, H. Rosing, J. Beijnen, 2008, Analytical and bioanalytical chemistry.

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

J. Schellens, J. Beijnen, A. Huitema, 2013, British journal of clinical pharmacology.

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

J. Schellens, J. Beijnen, E. Voest, 2007, Investigational New Drugs.

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

J. Beijnen, J. Schellens, D. Pluim, 1999, Analytical biochemistry.

Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next‐Generation Sequencing

H. Guchelaar, H. Gelderblom, J. Schellens, 2014, Clinical pharmacology and therapeutics.

Ciprofloxacin Strongly Inhibits Clozapine Metabolism

J. Schellens, J. Beijnen, M. Söhne, 2009, Clinical Drug Investigation.

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2001, British Journal of Cancer.

PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.

I. Meijerman, S. Harmsen, R. Maas-Bakker, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

J. V. Hasselt, L. Heyns, K. Calsteren, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

H. Rosing, J. Beijnen, J. Lieverst, 2002, British Journal of Cancer.

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53

J. Beijnen, M. V. van Velthuysen, J. Schellens, 2015, British Journal of Cancer.

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

J. Schellens, J. Beijnen, A. Huitema, 2012, Pharmaceutical Research.